Comparative Pharmacology
Head-to-head clinical analysis: AUREOMYCIN versus DECLOMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUREOMYCIN versus DECLOMYCIN.
AUREOMYCIN vs DECLOMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking aminoacyl-tRNA binding.
Binds to the 30S ribosomal subunit, inhibiting aminoacyl-tRNA binding to the mRNA-ribosome complex, thereby blocking protein synthesis.
250-500 mg orally every 6 hours; or 10-20 mg/kg/day intravenously divided every 12 hours
150 mg orally every 6 hours or 300 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 8–12 hours (prolonged in renal impairment; may extend to 20–30 hours in anuria)
Terminal elimination half-life 10-17 hours; prolonged to 18-48 hours in renal impairment
Renal (70% unchanged), biliary/fecal (30% as metabolites and unchanged drug)
Renal: ~50% unchanged; biliary/fecal: ~40% as inactive metabolites; enterohepatic recycling occurs
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic